Who are OnabotulinumtoxinA (Vistabel®)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Magnesium Sulfate, Intradetrusor Botox Injections, NT 201, Botox infiltration, Xeomin®, botulinum type a.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/onabotulinumtoxina-vistabel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

OnabotulinumtoxinA (Vistabel®) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OnabotulinumtoxinA (Vistabel®) (OnabotulinumtoxinA (Vistabel®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: botulinum toxin. Area: Neurology.

phase 3 botulinum toxin acetylcholine release Neurology Small molecule Live · refreshed every 30 min

Target snapshot

OnabotulinumtoxinA (Vistabel®) (OnabotulinumtoxinA (Vistabel®)) — Merz Pharmaceuticals GmbH. OnabotulinumtoxinA works by temporarily paralyzing muscles to treat various conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OnabotulinumtoxinA (Vistabel®) TARGET	OnabotulinumtoxinA (Vistabel®)	Merz Pharmaceuticals GmbH	phase 3	botulinum toxin	acetylcholine release
Magnesium Sulfate	Magnesium Sulfate	Pfizer	marketed	Electrolyte; anticonvulsant	Neuromuscular junction; motor nerve impulse; acetylcholine release	1981-01-01
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
NT 201	NT 201	Merz Aesthetics GmbH	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Xeomin®	Xeomin®	ATGC Co., Ltd.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery at neuromuscular junction)
botulinum type a	botulinum type a	Henry Ford Health System	marketed	Neurotoxin; botulinum toxin	SNARE proteins (synaptobrevin, SNAP-25, syntaxin); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (botulinum toxin class)

Merz Pharmaceuticals GmbH · 2 drugs in this class
Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OnabotulinumtoxinA (Vistabel®) — Competitive Intelligence Brief. https://druglandscape.com/ci/onabotulinumtoxina-vistabel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab